

This Product Highlights Sheet is an important document.

- It highlights the key terms and risks of this investment product and complements the Prospectus<sup>1</sup>.
- It is important to read the Prospectus before deciding whether to purchase the product. If you do not have a copy, please contact us to ask for one.
- You should not invest in the product if you do not understand it or are not comfortable with the accompanying risks.
- If you wish to purchase the product, you will need to make an application in the manner set out in the Prospectus.

## BLACKROCK GLOBAL FUNDS WORLD HEALTHSCIENCE FUND

<b>Product Type</b>	Investment Company	<b>Launch Date</b>	Class A: 6 April 2001 Class D: 12 November 2007
<b>Management Company</b>	BlackRock (Luxembourg) S.A.	<b>Custodian</b>	The Bank of New York Mellon SA/NV, Luxembourg Branch (which is the Depositary)
<b>Trustee</b>	Not applicable	<b>Dealing Frequency</b>	Generally every business day in Luxembourg
<b>Capital Guaranteed</b>	No	<b>Expense Ratio for the financial year ended 31 August 2019</b>	Class A: 1.82% Class D: 1.07%
<b>Name of Guarantor</b>	Not applicable		

### PRODUCT SUITABILITY

#### WHO IS THE PRODUCT SUITABLE FOR?

- The Fund is only suitable for investors who:
  - Seek to maximise total return.
  - Seek to invest in stocks of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
  - Are informed investors willing to adopt capital and income risk.

#### Further Information

Refer to “Investment Objective, Policy and Strategy” of the Singapore Prospectus for further information on product suitability.

### KEY PRODUCT FEATURES

#### WHAT ARE YOU INVESTING IN?

- You are investing in a sub-fund of BlackRock Global Funds (“BGF”).
- BGF is an open-ended investment company incorporated in Luxembourg and its home regulator is the Commission de Surveillance du Secteur Financier (CSSF).
- Non-Distributing Shares do not pay dividends whereas Distributing Shares pay dividends.
  - For Distributing (G), (R) and (S) Shares (if available): (i) dividends may come from capital of the Fund; (ii) this may reduce capital and the potential for capital growth of the Fund, and (iii) similar to other Distributing Shares, there is no guarantee of payout and the dividends may rise or fall.

Refer to “The Company” and “The Funds” of the Singapore Prospectus for further information on features of the product.

<sup>1</sup> The Prospectus is available for collection at the offices of the Singapore Representative during normal business hours or accessible at [www.blackrock.com/sg](http://www.blackrock.com/sg).

**Investment Strategy**

- The Fund invests globally at least 70% of its total assets in the equity securities of companies whose predominant economic activity is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology. Currency exposure is flexibly managed.
  - The Fund may invest directly up to 20% of its total assets in the PRC by investing via the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect.
  - The Fund may use derivatives for investment purposes and for the purposes of efficient portfolio management.
- Refer to “Investment Objective, Policy and Strategy” and “Use of Derivatives and Securities Lending” of the Singapore Prospectus for further information on investment strategy.

**Parties Involved**

- WHO ARE YOU INVESTING WITH?**
- The Management Company is BlackRock (Luxembourg) S.A.
  - The Management Company has delegated its investment management function of the Fund to one or more investment advisers within the BlackRock Group (as listed in paragraph 3.2 of the Singapore Prospectus).
  - The relevant investment adviser(s) may sub-delegate some of its/their functions to one or more sub-advisers within the BlackRock Group (as listed in paragraph 3.2 of the Singapore Prospectus).
  - The Depositary is The Bank of New York Mellon SA/NV, Luxembourg Branch.
  - The Singapore Representative is BlackRock (Singapore) Limited.
- Refer to “The Company”, “Management and Administration” and “Other Parties” of the Singapore Prospectus for further information on the role and responsibilities of these entities and what happens if they become insolvent.

**KEY RISKS**

- WHAT ARE THE KEY RISKS OF THIS INVESTMENT?**
- The price of Shares of the Fund and any income from them may fall as well as rise.
- These risk factors may cause you to lose some or all of your investment.**
- Refer to “Risk Factors” of the Singapore Prospectus for further information on risks of the product.

**Market and Credit Risks**

- **The Fund may be subject to Currency Risks**
  - Foreign currency exchange rate movements are likely to influence the returns to investors in Singapore, hence investors may be exposed to exchange rate risks.
  - For Hedged Share Classes, while the Fund attempts to hedge currency risks, there can be no guarantee that it will be successful in doing so.
- **The Fund may be subject to Emerging Market Risks**
  - The Fund may invest in one or more emerging markets and may be subject to a higher than average volatility than investing in more developed markets due to greater political, tax, economic, social, foreign exchange, custodial, liquidity, regulatory or other risks.
- **The Fund may be subject to Foreign Investment Restrictions Risks**
  - Some countries prohibit or restrict investment, or the repatriation of income, capital or the proceeds from sale of securities. The Fund may incur higher costs investing in these countries. Such restrictions may delay the investment or repatriation of capital of the Fund.
- **The Fund may be subject to Limited Market Sectors Risks**
  - The Fund’s investments are concentrated in the healthcare, pharmaceuticals and other healthscience sectors. This may subject the Fund to greater volatility and more rapid cyclical changes than more broad-based investments.
- **The Fund may be subject to Equity Risks**
  - The values of equities fluctuate daily and can be influenced by many factors including issuer-specific factors and broader economic and political developments.

## Liquidity Risks

- Redemptions may be suspended in certain circumstances detailed in the Prospectus.

## Product-Specific Risks

- **The Fund may be subject to Derivatives Risks**
  - The use of derivatives may expose the Fund to a higher degree of risk. Derivative contracts can be highly volatile and a relatively small market movement may have a potentially larger impact on derivatives than on standard bonds or equities. Leveraged derivative positions can hence increase the Fund's volatility. The Fund may sustain loss as a result of the failure of a derivatives counterparty to comply with the terms of the derivatives contract.
- **The Fund may be subject to the risks of Securities Lending**
  - The Fund may engage in securities lending. As such, the Fund will have a credit risk exposure to the counterparties to any securities lending contract. The Fund's investments can be lent to counterparties over a period of time. A default by the counterparty combined with a fall in the value of the collateral below that of the value of the securities lent may result in a reduction in the value of the Fund.
- **The Fund may be subject to Smaller Capitalisation Companies Risks**
  - The Fund may invest in small cap companies. Such investments may have higher than average volatility and liquidity risks.

## FEES AND CHARGES

### WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT?

#### Payable directly by you

<b>Initial Charge</b>	Class A: Up to 5%, Class D: Up to 5%
<b>Redemption Charge</b>	Nil <sup>^</sup>
<b>Conversion Charge</b>	Nil <sup>^</sup>

<sup>^</sup> A redemption charge of up to a maximum of 2% may be levied where *excessive trading* by a shareholder is suspected. A conversion charge of up to a maximum of 2% may be levied where *excessively frequent conversions* are made.

For more information about distributors' charges, please contact the relevant distributor through which you acquire your Shares.

#### Payable by the Fund from invested proceeds

<b>Management Fee<sup>2</sup></b> <b>(a) Retained by Management Company</b> <b>(b) Paid by Management Company to Singapore distributors (trailer fee)<sup>3</sup></b>	Class A: 1.50% p.a., Class D: 0.75% p.a. (a) 40% to 100% of Management Fee (b) 0% to 60% of Management Fee
<b>Administration Fee<sup>2</sup></b>	Currently up to 0.25% p.a.

Refer to "Fees, Charges and Expenses" and Appendix 1 of the Singapore Prospectus for further information on fees and charges.

<sup>2</sup> The combined Management and Administration Fees may be increased to up to a maximum of 2.25% in total by giving Shareholders 3 months' prior notice.

<sup>3</sup> Your Singapore distributor is required to disclose to you the amount of trailer fee it receives from the Management Company.

<b>Depository Fees</b>	Custody safekeeping fees: From 0.0024% to 0.45% p.a. Transaction fees: From US\$5.50 to US\$124 per transaction
<b>Securities Lending Fee</b>	The securities lending agent, BlackRock Advisors (UK) Limited, receives remuneration up to 37.5% of the net revenue from securities lending, with all operational costs borne out of BlackRock's share.

## VALUATIONS AND EXITING FROM THIS INVESTMENT

### HOW OFTEN ARE VALUATIONS AVAILABLE?

The net asset value of the Class A and Class D Shares for the previous dealing day may be obtained from the Singapore Representative or an appointed Singapore distributor and will also be published on [www.blackrock.com/sg](http://www.blackrock.com/sg).

Refer to "Obtaining Price Information" and "Redemptions" of the Singapore Prospectus for further information on valuation and exiting from the product.

### HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO?

- The Fund does not offer a cancellation period to investors.
- You may request to redeem your shares on any Dealing Day.
- Redemption proceeds are determined as follows:
  - o Redemption requests received, through the Investor Servicing Team or appointed Singapore distributors or otherwise, by the Transfer Agent by 6:00pm (Singapore time)<sup>4</sup> on any Dealing Day, will be accepted for that day's dealing.
  - o Redemption requests received by the Transfer Agent after this cut-off will be accepted for dealing on the next available Dealing Day.
- An example of how the gross redemption proceeds are calculated is as follows:

1,000 Shares	X	USD1.50 <sup>5</sup>	=	USD1,500
Redemption request		Net Asset Value per Share		Gross Redemption proceeds

"Dealing Day" means any Luxembourg business day on which the Fund is open for dealing.

- Redemption payments will normally be dispatched on the third Luxembourg business day after the relevant dealing day.

## CONTACT INFORMATION

### HOW DO YOU CONTACT US?

BlackRock (Singapore) Limited  
 Twenty Anson, #18-01, 20 Anson Road, Singapore 079912  
 Telephone: +65 6411-3000  
 Email: [clientservice.asiapac@blackrock.com](mailto:clientservice.asiapac@blackrock.com)  
 Website: [www.blackrock.com/sg](http://www.blackrock.com/sg)

**BlackRock**<sup>®</sup>

<sup>4</sup> The Singapore Representative and appointed Singapore distributors may impose their own more restrictive dealing deadlines on Shareholders in order to meet the Transfer Agent's dealing cut-off.

<sup>5</sup> For illustrative purposes only.